ScreenerHero

OTLKOutlook Therapeutics, Inc.

NAS · US · Healthcare · Biotechnology · outlooktherapeutics.com
0.6472USD-6.22%Mkt Cap: 157.06M $P/E: —

Outlook Therapeutics, Inc., operates as a clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for ophthalmic indications. Its lead product candidate is ONS-5010, an o…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$138.82BUSDP/E 31.9
REGN
Regeneron Pharmaceuticals, Inc.
$85.87BUSDP/E 20.5
ARGX
ARGENX SE
$61.34BUSDP/E 39.8
ARGX
argenx SE
$65.05BUSDP/E 39.6
MRNA
Moderna, Inc.
$57.94BUSD
UCB
UCB SA
$45.95BUSDP/E 19.6
RVMD
Revolution Medicines, Inc.
$44.89BUSD
ONC
BeOne Medicines AG
$42.36BUSDP/E 67.2
RPRX
Royalty Pharma Plc Class A
$35.43BUSDP/E 32.6
ALNY
Alnylam Pharmaceuticals, Inc.
$31.61BUSDP/E 41.2
BNTX
BioNTech SE
$29.28BUSD
INSM
Insmed Incorporated
$27.47BUSD
ROIV
Roivant Sciences Ltd. Common Shares
$26.22BUSD
INCY
Incyte Corporation
$25.91BUSDP/E 16.2
GMAB
Genmab A/S
$20.86BUSDP/E 26.3
GMAB
Genmab A/S
$19.26BUSDP/E 26.6
ASND
Ascendis Pharma A/S
$16.61BUSDP/E 19.6
JAZZ
Jazz Pharmaceuticals plc
$16.51BUSDP/E 17.4
BBIO
BridgeBio Pharma, Inc.
$15.93BUSD
EXEL
Exelixis, Inc.
$13.40BUSDP/E 17.0

Key Statistics

Company
Market Cap157.06M $
Enterprise Value—
Revenue (TTM)-1.16M $
Gross Profit57.21K $
Net Income (TTM)-62.42M $
Revenue/Share-0.0140 USD
Last Price0.6472 USD
Fiscal Year EndSep 2025
MR QuarterJun 2026
Employees17
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-4.83
PEG—
EV/EBITDA—
EV/Revenue—
P/S-141.18
P/B-1.13
EPS (TTM)-0.69
EPS (Forward)-0.14
52W Range
0.161015% of range3.390
52W High3.390 USD
52W Low0.1610 USD
Profitability
Gross Margin4.05%
Oper. Margin-120111.11%
EBITDA Margin0.00%
Profit Margin-4416.22%
ROE193.94%
ROA-335.90%
Growth
Revenue Growth-99.40%
Earnings Growth—
Cash Flow & Leverage
Operating CF-51.83M $
CapEx (TTM)—
FCF Margin—
FCF Yield—
Net Debt—
Net Debt/EBITDA—
Balance Sheet
Debt/Equity-0.94
Current Ratio—
Quick Ratio—
Book Value/Sh-0.5970 USD
Cash/Share—
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay DateMar 18, 2019
Splits
Last Split1:20
Split DateMar 14, 2024
Analyst Consensus
Rating1.5 (Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)4.900 USD
Upside (mean)+657.1%
Target Range1.600 USD – 10.00 USD
$1.600+657.1% to mean$10.00
# Analysts4
Ownership
Shares Out.242.67M
Float55.69M
Insiders12.64%
Institutions8.47%
Short Interest
Short Ratio1.4d
Short % Float11.54%
Short % Out.10.70%
Shares Short20.01M
Short (prev mo.)14.01M
Technical
SMA 501.278 (-49.4%)
SMA 2000.9033 (-28.3%)
Beta—
S&P 52W Chg18.16%
Avg Vol (30d)20.72M
Avg Vol (10d)36.69M
Technical Indicators
RSI (14)32.4
MACD-0.1432
MACD Signal-0.1039
MACD Hist.-0.0393
BB Upper1.376 USD
BB Middle0.9820 USD
BB Lower0.5885 USD
BB Width80.16%
ATR (14)0.1542 USD
Vol Ratio (20d)0.43x